DIAGNOSTIC ADJUNCTS TO CYTOPATHOLOGICAL DIAGNOSIS

细胞病理学诊断的辅助诊断

• 批准号: 6163416
• 负责人: A ABATI
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6163416
• 关键词: adolescence (12-20); biomarker; breast neoplasms; child (0-11); clinical research; cytodiagnosis; fine needle aspiration; human subject; human tissue; immunocytochemistry; lymphoma; melanoma; neoplasm /cancer diagnosis; tumor antigens

"Immunocytochemistry has proved to be a valuable diagnostic adjunct to cytopathologic diagnosis. The Cytopathology Section is involved in several clinically-related research projects, many of which utilize fine needle aspiration (FNA) and immunocytochemistry to provide ancillary diagnostic information regarding expression of various tumor antigens, HLA antigens or other markers. A partial listing of such studies includes: (1) Evaluation of percent of tumor cells expressing CD22 and CD19 in FNA specimens as part of a clinical trial using monoclonal antibody therapy for refractory lymphomas;(2) Cytologic diagnosis and immunophenotyping of ocular lymphomas; (3) characterization and application of a novel murine monoclonal antibody for malignant melanoma, MART-1 with subsequent quantitation of MART-1 in FNAs from malignant melanoma patients for treatment with anti-MART-1 antibody; (4) morphologic and immunocytochemical evaluation of bone marrow and peripheral blood samples for the detection of malignant cells in patients with stage IV breast cancer; (5) cytologic and immunocytochemical analysis of recently describeld antibodies for the differentialtion of malignant mesothelioma from adenocarcinoma;(6) Quantitation of CD3 positive lymphocytes in FNA specimens in malignant melanoma patients before and after immunotherapy;(7) utilization of cytokeratin antibodies in bone marrow and apheresis specimens for minimal residual disease and circulating tumor cell diagnoses in breast carcinoma patients.7) immunocytochemical evaluation of lymphoid populations in bronchoalveolar lavage specimens from patients subsequent to local exposure to endotoxin. ."

“事实证明，免疫细胞化学是有价值的 细胞病理诊断的诊断辅助。细胞病理学 部分参与了几个与临床有关的研究项目， 其中许多利用细针抽吸（FNA）和 免疫细胞化学可提供辅助诊断信息 关于各种肿瘤抗原，HLA抗原或 其他标记。此类研究的部分清单包括：（1） 评估表达CD22和CD19的肿瘤细胞百分比 FNA标本是使用单克隆抗体的临床试验的一部分 难治性淋巴瘤的治疗；（2）细胞学诊断和 眼淋巴瘤的免疫表型； （3）表征和 一种新型鼠单克隆抗体的应用恶性抗体 黑色素瘤，MART-1随后对MART-1进行定量 来自恶性黑色素瘤患者的FNA治疗 抗MART-1抗体； （4）形态学和免疫细胞化学 评估骨髓和外周血样本的 检测IV期乳腺癌患者的恶性细胞； （5）最近的细胞学和免疫细胞化学分析 描述恶性差异的抗体 来自腺癌的间皮瘤；（6）CD3的定量 FNA标本中恶性黑色素瘤的阳性淋巴细胞 免疫治疗前后的患者；（7）利用 骨髓中的细胞角蛋白抗体和射频标本的抗体 最小残留疾病和循环肿瘤细胞诊断 乳腺癌患者7） 来自支气管肺泡灌洗标本中的淋巴样种群 局部暴露于内毒素之后的患者。 。”